Disease Overview：Pulmonary embolism（PE）
Pulmonary embolism (PE) is a life-threatening condition caused by the obstruction of one or more pulmonary arteries—most commonly by thrombi originating from deep vein thrombosis (DVT) in the lower extremities. Risk factors include prolonged immobility, recent surgery, malignancy, pregnancy, oral contraceptive use, and inherited thrombophilias such as Factor V Leiden mutation. Clinical presentation ranges from asymptomatic to sudden dyspnea, pleuritic chest pain, hemoptysis, tachycardia, hypoxemia, and, in severe cases, hemodynamic instability or cardiac arrest. Diagnosis relies on clinical assessment (e.g., Wells score), D-dimer testing, and imaging—primarily CT pulmonary angiography (CTPA) or ventilation-perfusion (V/Q) scintigraphy. Management involves risk-stratified anticoagulation (e.g., low-molecular-weight heparin followed by direct oral anticoagulants), thrombolysis for massive PE, and, in select cases, catheter-directed thrombectomy or surgical embolectomy.
China offers distinct advantages for PE management: leading hematology and interventional pulmonology centers—such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital—employ advanced multimodal diagnostics, real-time intracardiac echocardiography, and next-generation CTPA with ultra-low-dose protocols. Their multidisciplinary PE response teams demonstrate >95% 30-day survival in intermediate-high-risk cohorts, supported by robust registries and published outcomes data. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based protocols or ICU-level monitoring. As a dedicated medical tourism agency, we facilitate seamless access for international patients—vetting JCI-accredited hospitals, coordinating specialist consultations, providing itemized, transparent pricing in advance, and delivering end-to-end support including visa assistance, medical translation, and post-discharge follow-up planning.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Pulmonary Embolism (Hematology Department)
Non-Surgical / Conservative Management
*Indicated for low- to intermediate-risk PE without hemodynamic instability or major contraindications to anticoagulation.*
- •Direct Oral Anticoagulants (DOACs)
- *Cost (30-day supply, USD):* - Rivaroxaban: $45–$68 - Apixaban: $52–$75 - Edoxaban: $40–$62
- •Parenteral Anticoagulation + Transition
- *INR monitoring (per test, 4–6 tests/month):* $8–$12/test
- •Baseline & Monitoring Labs/Exams (USD):
- CBC, renal/liver function panel: $22–$30 - Chest CT pulmonary angiography (CTPA): $185–$240 - ECG: $12–$18 - Arterial blood gas (ABG): $20–$28
Surgical / Procedural / Interventional Options
*Reserved for high-risk (massive) PE with hemodynamic collapse, contraindications to thrombolysis, or failure of medical therapy.*
- •Catheter-Directed Thrombolysis (CDT)
- *Procedure fee (including catheter, tPA infusion, ICU monitoring × 24h):* $2,100–$2,900 - *Pre-op workup (echocardiogram + CTPA + coagulation panel + ABG):* $320–$410
- •Surgical Pulmonary Embolectomy
- *Procedure fee (CPB, sternotomy, ICU × 3 days):* $4,800–$6,300 - *Pre-op workup (TEE + full cardiac assessment + CTPA + lactate + troponin):* $450–$580
- •Inferior Vena Cava (IVC) Filter Placement
- *Procedure fee (fluoroscopy-guided, filter device included):* $1,350–$1,780 - *Pre-op CTPA + renal function + coagulation screen:* $240–$310
Special / Complex Condition Management
- •Chronic Thromboembolic Pulmonary Hypertension (CTEPH):
- *Balloon Pulmonary Angioplasty (BPA):* $3,400–$4,600/session (typically 2–4 sessions)
- •Malignancy-Associated PE:
- *Oncology coordination + dose-adjusted monitoring:* $110–$150/month
Quick Selection Guide
- •Low-risk, young adult (<65), no comorbidities: DOAC monotherapy ($45–$75) + outpatient CTPA ($200) — *optimal first-line*.
- •Intermediate-high risk, elderly (>75) with renal impairment: LMWH bridging + warfarin ($42–$65) + enhanced lab monitoring ($120–$160) — *safer pharmacokinetics*.
- •Massive PE, SBP <90 mmHg, no bleeding risk: CDT ($2,100–$2,900) — *faster clot resolution than systemic lytics*.
- •Contraindicated to anticoagulation + recurrent PE: IVC filter ($1,350–$1,780) — *definitive mechanical prophylaxis*.
- •CTEPH confirmed on V/Q scan + right heart catheterization: PEA ($7,200–$9,500) — *curative intent in experienced centers*.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Pulmonary embolism Medical Vacation Packages
Curated transparent all-inclusive packages combining Pulmonary embolism treatment with China top medical destinations:
